Dynamic contrast‐enhanced MRI for oncology drug development. Issue 2 (8th February 2016)

• Record Type: Journal Article
• Authors: Sung, Yu Sub; Park, Bumwoo; Choi, Yoonseok; Lim, Hyeong‐Seok; Woo, Dong‐Cheol; Kim, Kyung Won; Kim, Jeong Kon
• Is Part Of: Journal of magnetic resonance imaging. Volume 44:Issue 2(2016)
• Page Start: 251
• Page End: 264
• Publication Date: 2016-02-08
• Subjects: DCE‐MRI -- validation -- qualification -- drug development; Magnetic resonance imaging -- Periodicals; 616
• DOI: 10.1002/jmri.25173
• Languages: English
• ISSNs: 1053-1807

Abstract

Abstract : Dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) is a promising tool for evaluating tumor vascularity, as it can provide vasculature‐derived, functional, and quantitative parameters. To implement DCE‐MRI parameters as biomarkers for monitoring the effect of antiangiogenic or vascular‐disrupting treatment, two crucial elements of surrogate endpoint, ie, validation and qualification, should be satisfied. Although early studies have shown the accuracy and reliability of DCE‐MRI parameters for evaluating treatment‐driven vascular alterations, there have been an increasing number of studies demonstrating the limitations of DCE‐MRI parameters as surrogate endpoints. Therefore, in order to improve the application of DCE‐MRI parameters in drug development, it is necessary to establish a standardized evaluation method and to determine the correct therapeutics‐oriented meaning of individual DCE‐MRI parameter. In this regard, this article describes the biophysical background and data acquisition/analysis techniques of DCE‐MRI while focusing on the validation and qualification issues. Specifically, the causes of disagreement and confusion encountered in the preclinical and clinical trials using DCE‐MRI are presented in detail. Finally, considering these limitations, we present potential strategies to optimize implementation of DCE‐MRI. J. Magn. Reson. Imaging 2016;44:251–264.